Seeking Greater Share of Oncology Dx Market, Roche Makes $3B Bid for Unresponsive Ventana | GenomeWeb
This story originally appeared in Biocommerce Week, a newsletter that has been discontinued.
Pushing to make its fourth acquisition in four months, Roche this week made an unsolicited offer to buy diagnostics firm Ventana Medical Systems for around $3 billion, or $75 per share — a 45 percent premium to Ventana’s closing price of $51.74 on Monday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.